Hepatitis

Scientists Replicate Hepatitis C Virus in Laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV. Scientists at the National Institute of Diabetes...

Norovirus, AIDS vaccine and Hepatitis Virus

Norovirus Prevalent in Those Suffering from Traveler's Diarrhea It is estimated that 20 to 50 percent of the pe...

Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis

OWL Genomics, biotechnological company, has presented at the CIC bioGUNE hold at the Bizkaia Technological Park (Derio), the first DNA chip concerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal, steatosis and NASH predisposed subjects. Non alcoholic steatohepatitis is a progressive disease of the liver of unknown etiology, ch...

UCLA study assesses cost-effectiveness of Hepatitis B drugs

Researchers at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System conducted the largest and most comprehensive study in comparing the cost-effectiveness of current modern drugs for treating hepatitis B -- a disease affecting 350 million worldwide. Published in the May 17 Annals of Internal Medicine, the study may help physicians worldwide in making treatment decisions. Re...

Natural Killers Could Lead to New Hepatitis Treatments

Researchers have discovered that natural killer T (NKT) cells, the immune system's sentinels, patrol the labyrinthine blood vessels of the liver for invaders or signs of tissue damage and demonstrate a dogged behavior not seen before in other T cells. The new studies show that NKT cells crawl along vessel walls, even upstream against blood flow. They halt only when they receive a chemical...

More>>

Hepatitis at Biology Products

ELISA Kit for Hepatitis B Surface Antigen Using GoldMag-AS Microparticles from BioChain

Description:The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Company:BioChain

Hepatitis at Biology Technology

Third Wave releases reagents for Hepatitis C testing

MADISON - The Hepatitis C virus is the leading cause of liver disease in the United States and affects 4 million Americans, leading to about 10,000 deaths annually, according to a co...

Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs

siRNA Construction Kit uses an in vitro transcription reaction and column purification to prepare transfection-ready siRNAs. With this kit, multiple siRNAs can be prepared in ~24 hours. Below is one example of how siRNAs prepared by the Silenc...

Southwestern lab selects Third Wave reagents for Hepatitis tests

MADISON, Wis. The reagents are part of tests that can identify all six types of the Hepatitis C virus, a blood-transmitted disease...

Hepatitis at Biology Definition

Hepatitis B

. Hepatitis B is recognized as <a href="/ ?...

Hepatitis at Medicine News

Tattoos may significantly increase risk of hepatitis C infection

It is a fad these days to sport tattoos. Kids often show off their sticker tattoos. But adults go a step further. Permanent tattoos, which are permanent reminders throughout life, in different designs and shapes, are very popular. However there is a darker side to the whole affair. The study in the United States of America says that tattoos significantly increase the risk of hepatitis C infe...

Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis

The sad part in the treatment of certain cancers, hepatitis and multiple sclerosis with interferon therapy is that while the treatment can extent life, it can seriously spoil its quality. Alpha interferon a drug used to fight these diseases can cause crippling depression. A new research now shows that the use of an antidepressant before starting the treatment can avoid this problem. Al...

Vitamin B for Hepatitis

A study has found a cheap and non toxic method of treating Hepatitis, by administering vitaminB to the Ptients. Hepatitis B virus infects the liver, and in severe cases can lead to cirrhosis, liver cancer and liver failure. It is spread through contact with the blood or body fluids of an infected person. A researcher decided to test thiamine for HBV after a very bright and aware...

Hepatitis G May Boost HIV Survival

A form of hepatitis virus not believed to cause illness may improve survival in people who have HIV, the virus that causes AIDS. In two new studies, HIV-positive people who were also infected with the hepatitis G virus tended to live longer than other people infected with HIV. Researchers suspect that hepatitis G, which is also known as GB virus C, improves survival by keeping HIV from replicatin...

Cure for Hepatitis B

An Indian medicinal plant may be one of the most effective ways of treating disorders caused by the Hepatitis B virus, according to new research. Clinical trials using a drug based on the Keezhanali plant were conducted at the University of Madras in South India and the Scottish Centre// for Infection in Glasgow. The results are believed to be better than any drug so far used to treat...

More>>

Hepatitis at Medicine Products

NOW® Hepatitis B Test

Description:The NOW Hepatitis B test is a rapid field or laboratory test for the differential diagnosis of a Hepatitis B infection. This simple, two-step test provides results in 10 minutes, allowing for accurate treatment and improved patient outcomes. Intended use: The NOW® Hepatitis B sAg/eAg test is an in vitro immunodiagnostic test for the detection of Hepatitis B surface antigen (HBsAg) an...
Company:Binax, Inc.

Autoimmune Hepatitis Panel Pluswith Reflex to Titers

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

Autoimmune Hepatitis Panelwith Reflex to ANA IFA Titer

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

Hepatitis A Virus Antibodies (Total)

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

Hepatitis A Virus Antibody, IgM

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

More>>

Hepatitis at Medicine Technology

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread is...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- AnadysPharmaceuticals, Inc. , a biopharmaceutical company committed tothe discovery, development and commercialization of novel medicinesfor the treatment of hepatitis and cancer, announced today that ithas nominated ANA598 as a candidate for clinical development as anorally-administered direct antiviral for the treatment of chronichepat...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed betweenvalopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting ofvalopicitabine (NM283), Idenix's lead dru...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 102, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The study showsthat Viread is no...

More>>

Hepatitis at Medicine Dictionary

Viral hepatitis

Alternate Names caused by the <a href="/ ?...

Hepatitis c

can be caused by <a href="/ ?q=/ Medicine...

Hepatitis b

. It can be mild, without symptoms, or it ma...

Hepatitis

<a href="/ ?q=/ Medicine-Dictionary/ t...

Hepatitis a

<A href="http:/ / www.medhelp.org/ glossary/ n...

More>>